Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-beta-ribofuranosyl-1,3-diazepinone
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
**Description:** 1-beta-ribofuranosyl-1,3-diazepinone is a synthetic small molecule classified as a nucleoside analog. It features a ribofuranosyl moiety linked to a diazepinone ring and is primarily studied for its ability to inhibit cytidine deaminase—an enzyme involved in nucleoside metabolism. By binding to the active site of cytidine deaminase and inhibiting its function, this compound prevents the conversion of cytidine to uridine. This mechanism has potential therapeutic implications in conditions where modulation of nucleoside metabolism is relevant (e.g., cancer chemotherapy). The compound has not been approved for clinical use and remains experimental[4][6][7].
- Other names
- 1-BETA-RIBOFURANOSYL-1,3-DIAZEPINONE1-beta-D-ribofuranosyl-1,3-dihydro-2H-1,3-diazepin-2-one1-(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-2,3-dihydro-1H–diazepin–2-one
02
Targets
CDA (Cytidine deaminase)
Beyond the preview
Go deeper on 1-beta-ribofuranosyl-1,3-diazepinone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-beta-ribofuranosyl-1,3-diazepinone.